UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.
GoSecure Partners with Northbridge Financial to Provide Incident Preparation and Response Services – Longview News-Journal
Summarize this content to a maximum of 60 words: GoSecure Partners with Northbridge Financial to Provide Incident Preparation and Response Services Longview News-Journal
